]>
IRCT20190120042419N1 IRCT 2019-02-09 Iran University of Medical Sciences Comparison of Rivaroxaban and Enoxaparin to Prevent Deep Vein Thrombosis Comparison of Rivaroxaban and Enoxaparin to Prevent Deep Vein Thrombosis in Patients with Pelvic Fracture 2019-01-24 anticipated 112 Complete https://irct.ir/trial/37022 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants were assigned after selected for study by block randomization method to Rivaroxaban and Enoxaparin groups, Blinding description: Participants will be blinding of the type of intervention received by other patients in this study. In addition, physician that examining the outcomes of the study will be blinded of the type of drugs. 3 Pelvic Fracture. Intervention 1: Intervention group: A dose of 10 milligrams Rivaroxaban will be giving orally once a day for two weeks. Intervention 2: Control group: Enoxaparin will be giving at a dose of 40 milligrams once a day subcutaneously for seven days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Has not been proposed in the research team.
public Peyman Hafezimoghadam
Rasoul Akram hospital, Niyayesh St, Sattarkhan St.
Tehran Iran (Islamic Republic of) 1445613131 +98 21 6652 5327 hafezimoghadam@yahoo.com Iran University of Medical Sciences scientific Peyman Hafezimoghadam
Iran University of Medical Sciences, Hemmat Highway
Tehran Iran (Islamic Republic of) 1449614535 +98 21 6652 5327 hafezimoghadam@yahoo.com Iran University of Medical Sciences Iran (Islamic Republic of) Patients with Pelvic Fracture No need for surgery no limit no limit Both Having kidney disease Use of anticoagulation drugs in less than a week Being pregnant Being in duration of breastfeeding Liver disease Having a head trauma S32.7 Multiple fractures of lumbar spine and pelvis Treatment - Drugs Treatment - Drugs Intervention group: A dose of 10 milligrams Rivaroxaban will be giving orally once a day for two weeks. Control group: Enoxaparin will be giving at a dose of 40 milligrams once a day subcutaneously for seven days. Deep Vein Thrombosis. Timepoint: Two times from the beginning of the study to distance two weeks. Method of measurement: Having any signs of pain in the leg. Bleeding. Timepoint: Two times from the beginning of the study to distance two weeks. Method of measurement: Any type of abnormal bleeding will be recorded in the during the study. Cost of intervention consumption. Timepoint: Deal of Drug consumption in during treatment. Method of measurement: Mean of consumption cost. Iran University of Medical Sciences Approved 2018-12-16 Ethics committee of Iran University of Medical Sciences Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)